

Special Issue

Novel Strategies to Mitigate Cancer Therapy Side Effects

Message from the Guest Editor

Although the effectiveness of cancer therapy has improved dramatically in the last few decades, side effects associated with small-molecule cancer drugs remain a tremendous health problem worldwide, as they negatively impact treatment outcome and diminish overall quality of life. The improved understanding of the molecular and/or cellular mechanisms that underlies the development of cancer therapy-induced side effects has resulted in continuing efforts to predict, prevent, and/or treat potentially debilitating adverse events. In this Special Issue, we invite experts from the field to highlight novel strategies to mitigate cancer therapy-induced side effects, including both predictive and preventative interventions (including those involving genotyping, biomarker phenotyping, population PK, targeted drug treatment), as well as innovative treatment approaches (including symptom management and mechanism-based reversal of injury).

Guest Editor

Dr. Shuiying Hu

Division of Outcomes and Translational Sciences, College of Pharmacy & Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA

Deadline for manuscript submissions

closed (22 November 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/82507

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)